Izetafin (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macrogol 3)

Izetafin is a combined electrolyte and osmotic laxative formulation used in clinical settings for fluid and electrolyte management and bowel preparation.

• Electrolyte imbalance: restores sodium, potassium and chloride levels in patients with dehydration.
• Constipation: provides an osmotic laxative effect to facilitate bowel movements.
• Diagnostic procedure preparation: used as a bowel cleansing agent before colonoscopy or imaging studies.

• Izetafin supplies essential electrolytes (sodium, potassium, chloride, sulfate) that are absorbed in the gastrointestinal tract to replenish fluid balance, while macrogol 3 (polyethylene glycol) acts as an osmotic agent that retains water in the intestinal lumen, softening stool and promoting evacuation without significant systemic absorption.

Izetafin may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild discomfort in the stomach.
• Abdominal bloating: feeling of fullness or swelling.
• Diarrhea: loose stools occurring after dosing.
• Flatulence: increased intestinal gas.
• Electrolyte disturbance: occasional mild shifts in serum levels.
• Headache: transient mild pain.

Serious or Rare Side Effects

• Severe dehydration: marked loss of fluids requiring medical attention.
• Electrolyte imbalance: significant hypo‑ or hyper‑natremia or hyper‑kalemia.
• Allergic reaction: rash, itching, or swelling.
• Abdominal pain: persistent or severe discomfort.
• Renal impairment: worsening kidney function in susceptible individuals.
• Hypotension: low blood pressure due to fluid shifts.

Before using Izetafin, consider the following safety measures.

• Assess hydration status: ensure patient is not severely dehydrated before administration.
• Monitor electrolytes: check serum sodium, potassium and chloride levels during therapy.
• Renal function: evaluate kidney function in patients with existing renal disease.
• Pregnancy and lactation: use only if clearly needed and prescribed by a healthcare professional.
• Concomitant laxatives: avoid simultaneous use of other osmotic agents to prevent excessive fluid loss.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Izetafin may interact with other medicines; awareness of potential interactions helps maintain safety.

Major Interactions (Avoid)

• Loop diuretics: may exacerbate electrolyte loss and dehydration.
• Potassium‑sparing agents: risk of hyper‑kalemia when combined.
• Antihypertensives: possible additive blood pressure lowering effect.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor renal function and electrolytes.
• NSAIDs: may affect renal perfusion when combined with electrolyte shifts.
• Other oral laxatives: increase risk of severe diarrhea and electrolyte disturbances.